Immunocore Holdings ADR earnings missed by $0.16, revenue fell short of estimates

Immunocore Holdings ADR (IMCR) reported Q3 EPS of -$0.28, missing estimates by $0.16, and revenue of $102.22M, below the $113.35M consensus. The stock is down 16.42% over 3 months and 10.75% over 12 months. Analysts revised EPS estimates 8 times negatively in the last 90 days. InvestingPro rates its financial health as 'fair performance'.

Original reporting
Published Nov 6, 2026, 6:19 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 6:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$IMCR
Bearish
high confidence
Mentioned
$IMCR
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$IMCRBearishMed
01

Why it matters

The earnings shortfall is likely to drive short-term price weakness, though longer-term catalysts remain unknown.

02

Market read

Company-specific earnings miss with limited broader market impact.

03

What to watch

Potential upcoming data readouts or partnership announcements not covered in the article.

Relevance 7/10Novelty 7/10Timing: after market close

Background

Immunocore Holdings ADR (NASDAQ: IMCR) reported its third-quarter results, missing both earnings per share and revenue expectations.

Company-level read

Ticker impact

$IMCRBearishHigh confidence
Context

Q3 earnings missed EPS and revenue estimates, EPS $-0.28 vs -$0.12 estimate, revenue $102.22M vs $113.35M estimate.

Expected impact

downward pressure as market prices in the earnings shortfall

Evidence & confidence

Both EPS and revenue came in below consensus, and the stock has already declined 16% over three months, suggesting investors will react negatively.

Market effects

Biotech sector may see modest pullback as earnings miss highlights execution risk.

Limited to US-listed biotech investors.

Low, confined to company-specific trade.

Counterpoint

The miss may be temporary; pipeline progress could support a rebound.

Key entities

  • Immunocore Holdings ADR

    Biotech firm listed on NASDAQ under ticker IMCR.

Related articles

$IMCRMed

Immunocore 3Q 2026: Revenue $102.22M, EPS ($0.28) — 10-Q Summary

Immunocore reported a 1.4% YoY revenue decline to $102.22M in Q3 2026, with a widened net loss of $14.22M. U.S. sales fell due to stocking adjustments and fewer sales weeks, partially offset by European and international growth. R&D spending increased, impacting results. KIMMTRAK is approved in 39 countries, and TEBE-AM Phase 3 trial enrollment is complete, with data expected in Q2 2027.